Vidya has announced the launch of ShataVida, a clinically researched dual-botanical blend designed for menopause support.
ShataVida combines Shatavari, a traditional Ayurvedic botanical known for supporting women’s health, with Ashoka Bark, a novel anti-inflammatory and antioxidant ingredient.
This unique blend was clinically studied in a placebo-controlled human trial, demonstrating progressive and sustained improvements across vasomotor, physical, emotional, sexual and sleep-related symptoms.
In addition to symptom relief, ShataVida supported hormonal balance by increasing estradiol (E2) and reducing follicle-stimulating hormone (FSH) levels — markers associated with improved menopausal adaptation.
“I am really excited to see that ShataVida offers clinical benefits for menopausal health at such a low material input,” said Dr Christopher Bailey, Director of Technical Business Development at Vidya.
“Ingredient options already on the market in this health benefit category are often limited in how formulators can use them due to high dose requirements.”
Standardised to ten per cent total saponins, ShataVida offers consistent potency in a low, formulation-friendly dose — making it an ideal foundation for next-generation women’s health formulations.